JPH11500139A - 新規成長因子およびそれをコードする遺伝子配列 - Google Patents
新規成長因子およびそれをコードする遺伝子配列Info
- Publication number
- JPH11500139A JPH11500139A JP8525903A JP52590396A JPH11500139A JP H11500139 A JPH11500139 A JP H11500139A JP 8525903 A JP8525903 A JP 8525903A JP 52590396 A JP52590396 A JP 52590396A JP H11500139 A JPH11500139 A JP H11500139A
- Authority
- JP
- Japan
- Prior art keywords
- molecule
- seq
- acid sequence
- amino acid
- similarity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 32
- 239000003102 growth factor Substances 0.000 title description 8
- 210000004027 cell Anatomy 0.000 claims abstract description 42
- 210000002569 neuron Anatomy 0.000 claims abstract description 20
- 230000035755 proliferation Effects 0.000 claims abstract description 17
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 55
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 55
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 54
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 49
- 239000002773 nucleotide Substances 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 29
- 125000003729 nucleotide group Chemical group 0.000 claims description 28
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 25
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 230000004083 survival effect Effects 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 10
- 230000004071 biological effect Effects 0.000 claims description 9
- 230000004663 cell proliferation Effects 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 7
- 230000003834 intracellular effect Effects 0.000 claims description 7
- 108020003175 receptors Proteins 0.000 claims description 7
- 102000005962 receptors Human genes 0.000 claims description 7
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 claims description 6
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims description 6
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 claims description 6
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 claims description 6
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 6
- 230000012292 cell migration Effects 0.000 claims description 6
- 102000058223 human VEGFA Human genes 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 210000003556 vascular endothelial cell Anatomy 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 210000000349 chromosome Anatomy 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 230000002441 reversible effect Effects 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 241000251468 Actinopterygii Species 0.000 claims description 2
- 241000271566 Aves Species 0.000 claims description 2
- 241000938605 Crocodylia Species 0.000 claims description 2
- 238000010171 animal model Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 244000144972 livestock Species 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 238000009395 breeding Methods 0.000 claims 2
- 230000001488 breeding effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 239000012636 effector Substances 0.000 abstract description 3
- 230000003511 endothelial effect Effects 0.000 abstract description 3
- 230000002792 vascular Effects 0.000 abstract description 3
- 230000008728 vascular permeability Effects 0.000 abstract description 3
- 230000003247 decreasing effect Effects 0.000 abstract description 2
- 230000010005 growth-factor like effect Effects 0.000 abstract description 2
- 210000005166 vasculature Anatomy 0.000 abstract description 2
- 101000742578 Mus musculus Vascular endothelial growth factor B Proteins 0.000 description 38
- 239000002299 complementary DNA Substances 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 238000003556 assay Methods 0.000 description 15
- 210000004498 neuroglial cell Anatomy 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 11
- 210000002216 heart Anatomy 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 210000005036 nerve Anatomy 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 210000002889 endothelial cell Anatomy 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 210000000278 spinal cord Anatomy 0.000 description 7
- 108700024394 Exon Proteins 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000033115 angiogenesis Effects 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 6
- 229920000669 heparin Polymers 0.000 description 6
- 210000004248 oligodendroglia Anatomy 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 5
- 108020004635 Complementary DNA Proteins 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 229940104230 thymidine Drugs 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 210000001428 peripheral nervous system Anatomy 0.000 description 4
- 210000001044 sensory neuron Anatomy 0.000 description 4
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 108020005345 3' Untranslated Regions Proteins 0.000 description 3
- 101100277337 Arabidopsis thaliana DDM1 gene Proteins 0.000 description 3
- 101000742579 Homo sapiens Vascular endothelial growth factor B Proteins 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 101150051432 SOM1 gene Proteins 0.000 description 3
- 108091036066 Three prime untranslated region Proteins 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 210000003486 adipose tissue brown Anatomy 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000004884 grey matter Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 210000002161 motor neuron Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000000508 neurotrophic effect Effects 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000007030 peptide scission Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000582631 Homo sapiens Menin Proteins 0.000 description 2
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 2
- 206010073150 Multiple endocrine neoplasia Type 1 Diseases 0.000 description 2
- 101000808007 Mus musculus Vascular endothelial growth factor A Proteins 0.000 description 2
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 230000002518 glial effect Effects 0.000 description 2
- 210000000777 hematopoietic system Anatomy 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000001153 interneuron Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 210000003540 papillary muscle Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 210000004129 prosencephalon Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 108700004121 sarkosyl Proteins 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 150000004992 toluidines Chemical class 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WTHNBLKUMCPUFE-UHFFFAOYSA-N (4-oxo-1,3,2,4lambda5-dioxathiaphosphetan-4-yl) phosphono hydrogen phosphate Chemical compound OP(=O)(O)OP(=O)(O)OP1(=O)OSO1 WTHNBLKUMCPUFE-UHFFFAOYSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101100393868 Arabidopsis thaliana GT11 gene Proteins 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108091060211 Expressed sequence tag Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 101150050678 MEN1 gene Proteins 0.000 description 1
- 102100030550 Menin Human genes 0.000 description 1
- 101100102907 Mus musculus Wdtc1 gene Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 102000003832 Nucleotidyltransferases Human genes 0.000 description 1
- 108090000119 Nucleotidyltransferases Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100035194 Placenta growth factor Human genes 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000006427 angiogenic response Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000001593 cAMP accumulation Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000003352 cell adhesion assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000003208 gene overexpression Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 102000047681 human MEN1 Human genes 0.000 description 1
- 102000056450 human PIGF Human genes 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000000933 neural crest Anatomy 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000002856 peripheral neuron Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000028742 placenta development Effects 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000019705 regulation of vascular permeability Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000002629 repopulating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000007441 retrograde transport Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 102220201851 rs143406017 Human genes 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229940016590 sarkosyl Drugs 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 210000000331 sympathetic ganglia Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU6647 | 1988-02-08 | ||
| AUPN1457A AUPN145795A0 (en) | 1995-03-02 | 1995-03-02 | A novel growth factor and a genetic sequence encoding same |
| AUPN6647A AUPN664795A0 (en) | 1995-11-20 | 1995-11-20 | A novel growth factor and a genetic sequence encoding same |
| AU1457 | 1995-12-22 | ||
| AU7274 | 1995-12-22 | ||
| AUPN7274A AUPN727495A0 (en) | 1995-12-22 | 1995-12-22 | A novel growth factor and a genetic sequence encoding same-II |
| PCT/AU1996/000094 WO1996027007A1 (en) | 1995-03-02 | 1996-02-22 | A novel growth factor and a genetic sequence encoding same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000178462A Division JP3683778B2 (ja) | 1995-03-02 | 2000-06-14 | 新規成長因子およびそれをコードする遺伝子配列 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH11500139A true JPH11500139A (ja) | 1999-01-06 |
Family
ID=27157841
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP8525903A Withdrawn JPH11500139A (ja) | 1995-03-02 | 1996-02-22 | 新規成長因子およびそれをコードする遺伝子配列 |
| JP2000178462A Expired - Lifetime JP3683778B2 (ja) | 1995-03-02 | 2000-06-14 | 新規成長因子およびそれをコードする遺伝子配列 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000178462A Expired - Lifetime JP3683778B2 (ja) | 1995-03-02 | 2000-06-14 | 新規成長因子およびそれをコードする遺伝子配列 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20070135344A1 (sv) |
| EP (1) | EP0815221B1 (sv) |
| JP (2) | JPH11500139A (sv) |
| KR (1) | KR100414615B1 (sv) |
| CN (1) | CN1194090C (sv) |
| AT (1) | ATE252600T1 (sv) |
| BR (1) | BR9607628A (sv) |
| CA (1) | CA2214439C (sv) |
| DE (1) | DE69630442T2 (sv) |
| ES (1) | ES2206558T3 (sv) |
| FI (1) | FI120153B (sv) |
| HK (1) | HK1002963A1 (sv) |
| HU (1) | HU223438B1 (sv) |
| NO (1) | NO320839B1 (sv) |
| NZ (2) | NZ337634A (sv) |
| WO (1) | WO1996027007A1 (sv) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5928939A (en) | 1995-03-01 | 1999-07-27 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-b and dna coding therefor |
| EP0873348A4 (en) * | 1995-06-06 | 2000-11-08 | Human Genome Sciences Inc | GROWTH FACTOR 3 OF THE HUMAN VASCULAR ENDOTHELIUM |
| EP0848755B2 (en) | 1995-09-08 | 2011-02-09 | Genentech, Inc. | Vegf-related protein |
| JP4086315B2 (ja) | 1995-09-29 | 2008-05-14 | ユニベルシタ デグリ スチュディ ディ シエナ | 調節遺伝子およびその使用 |
| US6994989B1 (en) | 1995-11-08 | 2006-02-07 | Immunex Corp. | FLK-1 binding proteins |
| WO1997017442A1 (en) | 1995-11-08 | 1997-05-15 | Immunex Corporation | Flk-1 binding protein |
| ES2251740T3 (es) | 1996-08-23 | 2006-05-01 | Ludwig Institute For Cancer Research | Factor de crecimiento de celulas de endotelio vascular d recombinante (vegf-d). |
| CA2287538A1 (en) * | 1997-04-25 | 1998-11-05 | Collateral Therapeutics | Truncated vegf-related proteins |
| IL137616A0 (en) | 1998-02-06 | 2001-07-24 | Collateral Therapeutics Inc | Variants of vegf-a |
| US7105481B2 (en) | 1998-11-10 | 2006-09-12 | Ludwig Institute For Cancer Research | Method for stimulating connective tissue growth or wound healing |
| NZ511379A (en) | 1998-11-10 | 2003-06-30 | Ludwig Inst Cancer Res | Platelet-derived growth factor D (PDGF-D), DNA coding therefor, and uses thereof for invasions of tumor cells |
| WO2000034474A2 (en) | 1998-12-07 | 2000-06-15 | Zymogenetics, Inc. | Growth factor homolog zvegf3 |
| US6783953B1 (en) | 1998-12-22 | 2004-08-31 | Janssen Pharmaceutica N.V. | Vascular endothelial growth factor-X |
| AUPQ568100A0 (en) * | 2000-02-16 | 2000-03-09 | Amrad Operations Pty. Limited | A method for producing recombinant molecules |
| US7026462B2 (en) | 2000-12-07 | 2006-04-11 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
| US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
| US7981863B2 (en) * | 2001-09-19 | 2011-07-19 | Neuronova Ab | Treatment of Parkinson's disease with PDGF |
| EP2314614B1 (en) | 2005-02-28 | 2015-11-25 | Sangamo BioSciences, Inc. | Anti-angiogenic methods and compositions |
| CN100448892C (zh) * | 2006-08-02 | 2009-01-07 | 中国人民解放军军事医学科学院基础医学研究所 | 抗肿瘤血管内皮生长因子受体vegf－r2抗原及其编码基因与应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5073492A (en) * | 1987-01-09 | 1991-12-17 | The Johns Hopkins University | Synergistic composition for endothelial cell growth |
| US5332671A (en) * | 1989-05-12 | 1994-07-26 | Genetech, Inc. | Production of vascular endothelial cell growth factor and DNA encoding same |
| US5219739A (en) * | 1989-07-27 | 1993-06-15 | Scios Nova Inc. | DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121 |
| US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| US5338671A (en) * | 1992-10-07 | 1994-08-16 | Eastman Kodak Company | DNA amplification with thermostable DNA polymerase and polymerase inhibiting antibody |
| JPH09510093A (ja) * | 1994-03-08 | 1997-10-14 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | 血管内皮細胞増殖因子２ |
| US5928939A (en) * | 1995-03-01 | 1999-07-27 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-b and dna coding therefor |
| US5607918A (en) * | 1995-03-01 | 1997-03-04 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-B and DNA coding therefor |
-
1996
- 1996-02-22 CN CNB961930357A patent/CN1194090C/zh not_active Expired - Lifetime
- 1996-02-22 AT AT96902810T patent/ATE252600T1/de active
- 1996-02-22 ES ES96902810T patent/ES2206558T3/es not_active Expired - Lifetime
- 1996-02-22 HU HU9800377A patent/HU223438B1/hu active IP Right Grant
- 1996-02-22 KR KR1019970706109A patent/KR100414615B1/ko not_active IP Right Cessation
- 1996-02-22 NZ NZ337634A patent/NZ337634A/en not_active IP Right Cessation
- 1996-02-22 WO PCT/AU1996/000094 patent/WO1996027007A1/en active IP Right Grant
- 1996-02-22 NZ NZ301611A patent/NZ301611A/en not_active IP Right Cessation
- 1996-02-22 BR BR9607628-3A patent/BR9607628A/pt not_active Application Discontinuation
- 1996-02-22 DE DE69630442T patent/DE69630442T2/de not_active Expired - Lifetime
- 1996-02-22 JP JP8525903A patent/JPH11500139A/ja not_active Withdrawn
- 1996-02-22 CA CA002214439A patent/CA2214439C/en not_active Expired - Lifetime
- 1996-02-22 EP EP96902810A patent/EP0815221B1/en not_active Expired - Lifetime
-
1997
- 1997-09-01 FI FI973571A patent/FI120153B/sv not_active IP Right Cessation
- 1997-09-02 NO NO19974035A patent/NO320839B1/no not_active IP Right Cessation
-
1998
- 1998-03-13 HK HK98102112A patent/HK1002963A1/xx not_active IP Right Cessation
-
2000
- 2000-06-14 JP JP2000178462A patent/JP3683778B2/ja not_active Expired - Lifetime
-
2006
- 2006-11-20 US US11/602,055 patent/US20070135344A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE69630442D1 (de) | 2003-11-27 |
| EP0815221A4 (en) | 1998-12-09 |
| CA2214439A1 (en) | 1996-09-06 |
| ATE252600T1 (de) | 2003-11-15 |
| HU223438B1 (hu) | 2004-07-28 |
| NZ301611A (en) | 2000-02-28 |
| CN1194090C (zh) | 2005-03-23 |
| EP0815221A1 (en) | 1998-01-07 |
| US20070135344A1 (en) | 2007-06-14 |
| ES2206558T3 (es) | 2004-05-16 |
| NO974035L (no) | 1997-11-03 |
| JP3683778B2 (ja) | 2005-08-17 |
| EP0815221B1 (en) | 2003-10-22 |
| FI973571A (sv) | 1997-10-30 |
| HK1002963A1 (en) | 1998-09-30 |
| JP2001037493A (ja) | 2001-02-13 |
| NZ337634A (en) | 2001-06-29 |
| KR19980702702A (ko) | 1998-08-05 |
| WO1996027007A1 (en) | 1996-09-06 |
| HUP9800377A3 (en) | 2000-12-28 |
| BR9607628A (pt) | 1999-11-30 |
| FI120153B (sv) | 2009-07-15 |
| CA2214439C (en) | 2002-12-17 |
| HUP9800377A1 (hu) | 1998-06-29 |
| DE69630442T2 (de) | 2004-08-19 |
| CN1224464A (zh) | 1999-07-28 |
| KR100414615B1 (ko) | 2004-05-27 |
| FI973571A0 (sv) | 1997-09-01 |
| NO320839B1 (no) | 2006-01-30 |
| NO974035D0 (no) | 1997-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20070135344A1 (en) | Novel growth factor and a genetic sequence encoding same | |
| Kocher et al. | Analysis of α-smooth-muscle actin mRNA expression in rat aortic smooth-muscle cells using a specific cDNA probe | |
| Grover et al. | The gene organization, chromosome location, and expression of a 55-kDa matrix protein (PRELP) of human articular cartilage | |
| US7932352B2 (en) | Semaphorin genes (I) | |
| EP0960937B1 (en) | Novel semaphorin gene: semaphorin y | |
| US6576441B1 (en) | Semaphorin Z and gene encoding the same | |
| US7160991B1 (en) | Vascular endothelial growth factor polypeptides | |
| AU707513B2 (en) | A novel growth factor and a genetic sequence encoding same | |
| PL185293B1 (pl) | Izolowany polipeptyd, izolowana cząsteczka kwasu nukleinowego, sposób otrzymywania polipeptydu, cząsteczka antysensowna, środek farmaceutyczny, komórka gospodarza oraz wektor | |
| JP2000503764A (ja) | 増殖性動脈疾患の診断および治療におけるｒｃ―９の使用 | |
| WO1997017982A1 (en) | Methods and compositions for hair growth promotion | |
| Lagercrantz et al. | Sequence and expression of the mouse homologue to human phospholipase C β3 neighboring gene | |
| US5767262A (en) | Smooth muscle cell LIM protein | |
| April et al. | The cloning and characterization of chick tyrosinase from a novel embryonic cDNA library | |
| AU660215B2 (en) | Mammalian Sos - a regulator/effector of tyrosine kinase signalling | |
| WO2000052462A1 (en) | Heart abnormalities in vascular endothelial growth factor b (vegf-b) deficient animals and methods relating to these heart abnormalities | |
| Khoo | Isolation and characterization of the putative MIH gene sequence from the lobster Jasus edwardsii. | |
| JP2001258575A (ja) | βアミロイドにより誘導できる遺伝子 | |
| JPH0838183A (ja) | カルデスモン転写調節領域 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20040302 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040527 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040712 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20040901 |